Prasco Acquires Rights to Authorized Generic of Adderall XR®

Washington, DC – October 17, 2016 – Cooley advised Prasco Laboratories on its agreements with Teva Pharmaceutical Industries and Shire to acquire the rights to distribute authorized generic versions of Adderall XR® Extended Release Capsules, and represented Prasco before the Federal Trade Commission in obtaining approval for the acquisition.

The FTC required Teva to divest its authorized generic versions of Adderall XR – available in 5 mg, 10 mg, 15 mg, 20 mg and 30 mg capsules – as a precondition to acquiring Allergan plc’s generics business.

Prasco is a privately held healthcare company with more authorized generic partnerships than any other company.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Howard Morse Partner, Washington, DC
Kenneth Krisko Partner, Reston
Christian Plaza Partner, Reston
Wendy Goldstein Partner, New York
Erich Veitenheimer Partner, Washington, DC
David Burns Associate, Washington, DC
Marc Samuel Special Counsel, Washington, DC
Sandhya Deo Associate, Washington, DC